Back to Search
Start Over
Retrospective Evaluation of Melphalan, Vincristine, and Cytarabine Chemotherapy for the Treatment of Relapsed Canine Lymphoma.
- Source :
- Journal of the American Animal Hospital Association; Jan/Feb2024, Vol. 60 Issue 1, p7-14, 8p
- Publication Year :
- 2024
-
Abstract
- Dogs diagnosed with multicentric lymphoma often relapse following induction therapy within the first year of treatment. The primary aim of this study was to evaluate the tolerability of a novel drug combination using melphalan, vincristine, and cytarabine (MOC) for the treatment of relapsed lymphoma. On day 1, dogs were treated with vincristine (0.5–0.6 mg/m<superscript>2</superscript> IV) and cytarabine (300 mg/m<superscript>2</superscript> IV over 4–6 hr or subcutaneously over 2 days). On day 7, dogs were treated with melphalan (20 mg/m<superscript>2</superscript>per os). This 2 wk protocol was repeated for at least three cycles or until treatment failure. Twenty-six dogs were treated with MOC and met the inclusion criteria. Twenty-three dogs had toxicity data, and all experienced adverse events with the majority graded as mild. The overall response rate was 38%, which included 19% of dogs who achieved a complete response. The median progression-free survival was 29 days (range 1–280 days). The overall clinical benefit was 65% for a median of 37 days (range 33–280 days). MOC is a safe treatment option for relapsed lymphoma in dogs. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 05872871
- Volume :
- 60
- Issue :
- 1
- Database :
- Supplemental Index
- Journal :
- Journal of the American Animal Hospital Association
- Publication Type :
- Academic Journal
- Accession number :
- 174603603
- Full Text :
- https://doi.org/10.5326/JAAHA-MS-7372